Market for Pharmaceutical contract manufacturing will reach $84.0bn in 2020, according to new visiongain data

31 August 2018
Pharma

A new report by visiongain forecasts that overall pharmaceutical contract manufacturing market will achieve revenues of $84.0 billion in 2020, at a compound annual growth rate of 6.4% from 2015 to 2020. The market is expected to continue to grow from 2016 to 2026 as the pharmaceutical companies are strategically outsourcing services. That revenue prediction and others appear in Pharma Leader Series: Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2016-2026.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand commercial prospects of industries and markets in healthcare and other fields.

This updated study discusses market-leading companies, the strategies they have employed to grow in the past few years, and how they will continue to expand to 2026. The study analyses deals, commercial prospects and financial performances of 30 leading pharmaceutical CMOs in the following regions:

• North America
• Europe
• Japan
• China
• India

In particular it discusses revenue prospects, including forecasts, analysis of the operational performance and forecast profitability of some leading CMOs. The new investigation also discusses forces driving and restraining individual firms and provides competitive intelligence for companies operating in the pharmaceutical contract manufacturing market. It also examines opportunities and challenges for individual firms and strategies that can be employed to maximise performance from 2016 to 2026.

In 2015, out of all the contract manufacturing services, API Manufacturing continues to hold the largest share of the total market revenue like last year. In parallel, FDF manufacturing shows the fastest growth. Geographically, developed countries hold the maximum share of the outsourcing. North America holds the largest market share of the industry. This study shows that pharmaceutical companies will continue to outsource mainly in developed countries. However, the Indian and Chinese markets are growing at a faster rate as compared to the CMO market in developed countries.

Shruti Tayal, a pharmaceutical industry analyst at visiongain said: “Within pharmaceutical contract manufacturing, active pharmaceutical ingredient (API) continues to form the largest revenue producing segment in 2015. Final dosage form (FDF) continues to expand at the fastest rate from 2016 to 2026. Leading CMOs will capture most of the customers owing to integrated service offerings, also benefiting from consolidation in that pharma service industry. Pharmaceutical companies will continue to outsource some manufacturing operations to save time and money in emerging regions such as India, China and Latin America. Those firms will increase competition in the developing national CMO markets. India and China are already prominent for contract production of APIs and FDFs for domestic use and export. That trend will continue, with opportunities also remaining for CMO operations in North America, Europe, Japan and other established markets, especially for high-value biological drug products”.

Visiongain’s new investigation identifies main trends and revenue predictions at overall world market and individual company level.

This report discusses company profiles, recent mergers and acquisitions and analysis of the company’s recent financial performance. A SWOT analysis and forecast for all 5 firms, in the period of 2016-2026.

- The leading CMOs in North America:
• Catalent
• Patheon
• Baxter
• Abbvie
• Pfizer

- The leading CMOs in Europe:
• Lonza
• Evonik Degussa
• Royal DSM
• Boehringer Ingelheim
• Fareva
• Aenova
• Famar
• Vetter
• Almac
• Delpharm
• Siegfried
• Corden Pharma
• Recipharm
• Aesica

- The leading CMOs in Japan:

• Nipro
• Daito

- 3 leading API specialists:

• Teva API
• Esteve Quimica
• Euticals

- China’s 3 leading CMOs:

• Zhejiang Hisun Pharmaceuticals
• Zhejiang Huahai Pharmaceuticals
• Shandong Xinhua Pharmaceuticals

- Indian’s 3 leading CMOs:

• Aurobindo Pharma
• Divis Laboratories
• Dr. Reddy’s Laboratories

Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) – Market, Industry, Trends, Technologies and Prospects 2016-2026 adds to visiongain’s analytical reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, medical devices, diagnostics, national markets, biotechnologies and outsourced services.

Recent News

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2021-2031

Increasing demand for medical products in developing as well developed economies coupled with rising ageing population is expected to open new opportunities for medical device contract manufacturing industry over the forecast period.

01 December 2020

Read

Visiongain Publishes Virus Testing Diagnostic Kits Market Report 2021-2031

With the growing burden of rare diseases around the world, there has been a rise in the requirement for proper diagnosis as well as full proof treatment positions for various chronic diseases. With increasing awareness regarding symptoms of various terminal illnesses, the diagnosis rates have been improving in developing countries such as China, India, Japan, Brazil, and other southeast Asian countries.

01 December 2020

Read

Visiongain Publishes RNA Analysis/Transcriptomics Market Report 2020-2030

Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.

30 November 2020

Read

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever